IL-18BP是一种分泌的免疫检查点,也是IL-18免疫治疗的障碍
Ting Zhou1, William Damsky2, Orr-El Weizman1
1Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Nature
|June 26, 2020
概括
通过抵抗IL-18结合蛋白 (IL-18BP) 的抑制来克服瘤的抗性. 这种新疗法增强了抗瘤免疫力和T细胞功能,
科学领域:
- 免疫学
- 癌症生物学
- 治疗发展
背景情况:
- 细胞因子是已知的晚期癌症免疫疗法,但有效性和耐受性有限.
- 互白素-18 (IL-18) 途径有望增强抗瘤免疫力,但之前的复合IL-18疗法缺乏临床疗效.
- 诱惑受体IL-18结合蛋白 (IL-18BP) 在瘤中升高调节,并阻碍IL-18的抗瘤活性.
研究的目的:
- 研究IL-18BP在限制IL-18免疫疗法的作用.
- 设计一种抗IL-18BP抑制的新型IL-18.
- 在临床前癌症模型中评估这种工程IL-18的治疗潜力.
主要方法:
- 使用定向进化来制造一种抗诱的IL-18 (DR-18) 变种.
- 评估了DR-18克服IL- 18BP抑制和维持信号潜力的能力.
- 在小鼠瘤模型中评估了DR-18的抗瘤作用,分析了T细胞群和自然杀手细胞活性.
主要成果:
- 改造的DR-18在小鼠模型中表现出强大的抗瘤作用,与野生型IL-18不同.
- DR-18促进了多功能效应体CD8+ T细胞和扩展的干状TCF1+前体CD8+ T细胞.
- DR-18 降低了耗尽的 CD8+ T 细胞 (TOX+) 和增强了自然杀手细胞活性,有效治疗了抗PD-1 治疗耐药且缺乏 MHC I 类的瘤.
结论:
- IL-18BP是基于IL-18的癌症免疫疗法的重要障碍.
- 设计的抗诱IL-18 (DR-18) 是克服瘤抗性的有希望的治疗策略.
- IL-18 途径具有开发下一代癌症免疫疗法的巨大潜力.
相关概念视频
T Cell Types and Functions
1.9K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.9K
Tumor Immunotherapy
1.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K


